title: Beneficial effect of myricetin on renal functions in streptozotocin-induced diabetes.
abstract: Myricetin is a naturally occurring flavonoid that is known to decrease plasma glucose levels in diabetes; however, its influence on renal functions has not yet been determined. This study investigated the effect of myricetin on structural and functional changes occurring in diabetic nephropathy. Male Albino Wistar rats were divided into three groups: normoglycemic, diabetic and myricetin-treated diabetic. Diabetes was induced by intraperitoneal (ip) injection of streptozotocin (50 mg/kg), and rats having fasting blood glucose (FBG) levels greater than 200 mg/dl were included in the study. Treatment of myricetin (6 mg/day ip) was initiated 16 weeks after diabetes was confirmed. Light microscopy was performed on hematoxylin-eosin- and Masson's trichrome-stained sections to evaluate the effect of myricetin on structural changes in the kidney, while creatinine clearance, blood urea nitrogen (BUN), kidney weight, urine volume and protein were measured to assess kidney functions. Activities of glutathione peroxidase (GPx) and xanthine oxidase (XO) were also measured in renal tissues obtained from all experimental groups. Myricetin treatment significantly decreased glomerulosclerosis and reduced BUN, urinary volume and protein excretion, which was profoundly increased in diabetic rats. Decreased creatinine clearance measured in diabetic rats was significantly increased following myricetin treatment. Myricetin also restored altered renal activities of GPx and XO, which were decreased and increased in diabetic rats, respectively. In conclusion, myricetin improved altered renal functions and restored renal activities of GPx and XO in diabetic rats. Obtained data suggest that myricetin could be of therapeutic potential in diabetic nephropathy.
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Akdeniz University, 07070 Antalya, Turkey.
authors.forename: Filiz
authors.initials: F
authors.lastname: Ozcan
authors.forename: Asli
authors.initials: A
authors.lastname: Ozmen
authors.forename: Bahar
authors.initials: B
authors.lastname: Akkaya
authors.forename: Yakup
authors.initials: Y
authors.lastname: Aliciguzel
authors.forename: Mutay
authors.initials: M
authors.lastname: Aslan
mesh_terms: D000818:Animals; D001806:Blood Urea Nitrogen; D003404:Creatinine / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D003928:Diabetic Nephropathies / Q000473:pathology / Q000517:prevention & control*; D005419:Flavonoids / Q000008:administration & dosage*; D006651:Histocytochemistry; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007668:Kidney / Q000187:drug effects* / Q000502:physiology*; D008657:Metabolic Clearance Rate; D008853:Microscopy; D011507:Proteinuria; D051381:Rats; D017208:Rats, Wistar; D016896:Treatment Outcome; D014556:Urine / Q000737:chemistry
chemical_list: D005419:Flavonoids; D007004:Hypoglycemic Agents; C040015:myricetin; D003404:Creatinine
references.citation: Diabetes. 1993 Feb;42(2):363-6
references.pmid: 8381096
references.citation: Life Sci. 2000 Aug 25;67(14):1695-705
references.pmid: 11021354
references.citation: Physiol Res. 2001;50(6):537-46
references.pmid: 11829314
references.citation: Diabetes. 2005 Dec;54(12):3435-41
references.pmid: 16306359
references.citation: Am J Physiol Renal Physiol. 2006 Aug;291(2):F495-502
references.pmid: 16609147
references.citation: Clin Chem. 1971 Aug;17(8):696-700
references.pmid: 5562281
references.citation: Biochem Pharmacol. 1996 Feb 23;51(4):423-9
references.pmid: 8619886
references.citation: Am J Physiol Renal Physiol. 2005 Nov;289(5):F1040-7
references.pmid: 15956780
references.citation: Diabetes Technol Ther. 2010 Jun;12(6):491-501
references.pmid: 20470234
references.citation: Endocr Metab Immune Disord Drug Targets. 2006 Mar;6(1):77-93
references.pmid: 16611166
references.citation: J Diabetes Complications. 2004 Sep-Oct;18(5):282-8
references.pmid: 15337502
references.citation: Metabolism. 1990 Aug;39(8):787-93
references.pmid: 2198430
references.citation: J Pharm Biomed Anal. 2006 Aug 28;41(5):1614-9
references.pmid: 16554139
references.citation: N Engl J Med. 2000 Feb 10;342(6):381-9
references.pmid: 10666428
references.citation: Pancreas. 1991 Jan;6(1):54-62
references.pmid: 1994380
references.citation: Biochemistry. 1992 Sep 1;31(34):8059-63
references.pmid: 1324726
references.citation: Exp Biol Med (Maywood). 2008 Jan;233(1):4-11
references.pmid: 18156300
references.citation: J Lab Clin Med. 1967 Jul;70(1):158-69
references.pmid: 6066618
references.citation: Diabetes Care. 2005 Jan;28(1):164-76
references.pmid: 15616252
references.citation: Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S178-81
references.pmid: 11576950
references.citation: Gen Pharmacol. 1997 Aug;29(2):121-6
references.pmid: 9251891
references.citation: Cell Mol Biol (Noisy-le-grand). 2007 May 30;53(5):68-78
references.pmid: 17543235
references.citation: Clin Chem. 1993 Dec;39(12):2522-6
references.pmid: 8252725
references.citation: Free Radic Biol Med. 1989;6(6):607-15
references.pmid: 2753392
references.citation: Pediatr Nephrol. 2009 Jun;24(6):1173-80
references.pmid: 19224250
references.citation: J Lab Clin Med. 2003 Sep;142(3):172-7
references.pmid: 14532905
references.citation: Hypertension. 1985 May-Jun;7(3 Pt 1):398-404
references.pmid: 3158604
references.citation: Planta Med. 1991 Jun;57(3):208-11
references.pmid: 1896517
references.citation: Acta Endocrinol (Copenh). 1981 Nov;98(3):432-6
references.pmid: 7293670
references.citation: Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):97-103
references.pmid: 16433898
references.citation: Diabet Med. 1998 Jul;15(7):539-53
references.pmid: 9686693